Innovation in Drug Delivery: The future of nanotechnology and non-invasive protein delivery

Table of Contents

Executive Summary

• Introduction
• Advances in nanotechnology
• Targeted therapies in oncology
• Innovation in pulmonary delivery
• Innovation in transdermal delivery
• Innovation in medical devices: stents and implants
• Competitive landscape
• The future of drug delivery

Chapter 1 Introduction

• Summary
• Introduction
• Key indications
• Key trends
• Cost and revenue implications of innovative technology
• Drivers of innovation
• Poor patient compliance and injectable protein delivery
  • Needle-free injections
  • Non-invasive protein delivery
• Poor solubility
  • Formulation technologies for poorly soluble compounds
• Reducing drug dosage frequency
  • Combination products
  • Controlled release
• Conclusions and key findings

Chapter 2 Advances in nanotechnology

• Summary
• Introduction
• Advantages of nanotechnology for drug delivery
• Marketed products using nanotechnology
• Abraxane
• Doxil
• Potential for nanotechnology in drug delivery
• Injectable delivery
• Implantable delivery systems
• Oral delivery
• Transdermal delivery
• Competitive landscape
• Elan
• Flamel Technologies
• Michigan Nanotechnology Institute for Medicine and Biological Sciences
• Abraxis BioScience
• Others
• The future of nanotechnology in drug delivery
• Delivering cancer stem cell therapies
• siRNA and gene therapy
• Conclusions and key findings

Chapter 3 Targeted therapies in oncology

• Summary
• Introduction
• Targeted therapies overview
• Nanotechnologies to target cancers
• Stealth
• Transdrug
• NanoCrystal
• Monoclonal antibodies
• Pipeline mAbs
• Antibody fragments
  • PEGylation
  • UniBody technology
• Inhaled monoclonal antibodies
• Oral monoclonal antibodies
• Drug delivery to brain tumors
• Stem cell therapy
• Synthetic toxins
• Viral delivery systems
• RNAi in chemotherapy
• Conclusions and key findings

Chapter 4 Innovation in pulmonary delivery

• Summary
• Introduction
• Advantages and disadvantages of pulmonary delivery
• Advantages
• Disadvantages
• Key pulmonary delivery pipeline
• Key indications for pulmonary drug delivery
• Asthma and COPD
• Diabetes
  • Inhaled insulin pipeline
• CNS disorders
• Infectious diseases
• Other indications
• Conclusions and key findings

Chapter 5 Innovation in transdermal

• delivery
• Summary
• Introduction
• Transdermal drug delivery pipeline
• Transdermal patch technologies
• Passive patch
  • Noven Pharmaceuticals
  • Iomai
• Active patches
  • ZARS Pharma
  • ALZA Corporation
  • Altea Therapeutics
  • TransPharma Medical
• Future of transdermal drug delivery
• Conclusion and key findings

Chapter 6 Innovation in medical devices:

• stents and implants
• Summary
• Introduction
• Implants
• Injectable solid implants
• Injectable microparticles
• Drug-eluting stents
• Marketed stents
  • Cypher
  • Taxus
  • Xience
• Clinical trials
• Cost effectiveness
• Adverse events
• Drug-eluting stent pipeline
  • ZoMaxx
  • Endeavor
• Next generation drug-eluting stents
• Controlled-release implantable microchips
• MEMS technologies
• Conclusions and key findings

Chapter 7 Competitive landscape

• Summary
• Introduction
• Leading innovative drug delivery companies
• Altea Therapeutics
• Pipeline
• Strategic and growth analysis
• ALZA Corporation
  • Pipeline
  • Strategic and growth analysis
• Elan
  • Pipeline
  • Strategic and growth analysis
• Emisphere
  • Pipeline
  • Strategic and growth analysis
• Nektar
  • Pipeline
  • Strategic and growth analysis
• Key M&A and licensing activity
• Drug delivery business strategy
• M&A activity in drug delivery

Chapter 8 The future of drug delivery

• Summary
• Introduction
• Nanotechnology
• siRNA
• Stem cells
• Transmucosal drug delivery
• Conclusions and key findings

Chapter 9 Appendix

• IMS data
• Bibliography
• Index

List of Figures

• Figure 1.1: Drivers of innovation in drug delivery
• Figure 2.2: Sales of Abraxane, Taxol and generic paclitaxol in the US and 5EU, 2005-6
• Figure 2.3: Doxil structure
• Figure 3.4: Targeted oncology pipeline by indication, 2006
• Figure 3.5: Sales of marketed oncology mAbs, 2004-5
• Figure 4.6: Inhaled insulin market forecast, 2006-2015
• Figure 4.7: Aradigm pain management AERx device
• Figure 4.8: Sales forecasts of MedImmunes FluMist and CAIV-T in the US, 2004-2011
• Figure 5.9: Transdermal drug delivery pipeline by therapy area, 2006
• Figure 5.10: ALZA' s E-TRANS delivery system
• Figure 6.11: Biophan' s nanomagnetic particle-based technology
• Figure 7.12: Capabilities of leading innovative drug delivery companies, 2006
• Figure 7.13: Licensing and collaboration strategy of leading innovative drug delivery companies

List of Tables

• Table 1.1: Key companies specializing in long-acting injection technology
• Table 2.2: Nanoparticles as drug delivery carriers
• Table 2.3: Sales of cancer nanomedicine marketed products in the US and 5EU, 2005-6
• Table 2.4: Key nanotechnology/nanomedicine deals, 2005-2006
• Table 2.5: Sales of marketed products using Elan' s NanoCrystal technology in the US and 5EU, 2005-6
• Table 2.6: Flamel' s product pipeline using the Medusa platform, 2006
• Table 3.7: Key pipeline oncology drugs using nanotechnology, 2006
• Table 3.8: Late stage oncology monoclonal antibody pipeline, 2006
• Table 3.9: Antibody fragment pipeline, 2006
• Table 3.10: Chemotherapeutic siRNA targets
• Table 4.11: Key pulmonary/inhalable delivery pipeline, 2006
• Table 4.12: Key pulmonary insulin pipeline, 2006
• Table 5.13: Key late-stage transdermal patches, 2006
• Table 5.14: Transdermal patch technology companies, 2006
• Table 6.15: Key clinical trial with drug-eluting stents, 2006
• Table 6.16: Comparison of costs for bare-metal and drug-eluting coronary stents, 2004
• Table 6.17: Drug eluting stent pipeline, 2006
• Table 7.18: Altea Therapeutic' s pipeline, 2006
• Table 7.19: ALZA' s core technologies, 2006
• Table 7.20: ALZA Therapeutics' pipeline, 2006
• Table 7.21: ALZA' s drug delivery deals, 2005-6
• Table 7.22: Elan' s R&D pipeline, 2006
• Table 7.23: Elan' s drug delivery deals, 2005-6
• Table 7.24: Emisphere' s pipeline, 2006
• Table 7.25: Emisphere' s drug delivery deals, 2005-6
• Table 7.26: Nektar' s key innovative pipeline products, 2006
• Table 7.27: Nektar Therapeutics' drug delivery deals, 2005-6
• Table 7.28: Drug discovery and technology deals made by the top 20 pharmaceutical companies, 2000-04
• Table 7.29: Key drug delivery M&A activity, 2006